The cancer–immune dialogue subject to immuno-oncological intervention is profoundly
influenced by microenvironmental factors. Indeed, the mucosal microbiota—and more …

Immune checkpoint inhibitors (ICIs) have dramatically improved patient outcomes in a
variety of tumor types, but with variable efficacy. Recent research has suggested that …

The gut microbiota plays a critical role in the anti-tumor immune response. There is
increasing data showing that antibiotics (ATBs) change the composition of the gut microbiota …

Objectives Observational and experimental studies suggest that the use of antibiotics close
to administration of immune checkpoint inhibitors (ICI) can have a negative effect on tumour …

Abstract Objective Immune checkpoint inhibitors (ICIs) have recently achieved inspiring
performance in improving the prognosis of various solid tumors. Gut microbiome plays a …

Antibiotic (ATB) use seems to negatively affect the outcomes of immune checkpoint
inhibitors (ICIs). The aim of this review is to clarify whether ATB use influences the efficacy of …

Background: Patients with metastatic non-small cell lung cancer (NSCLC) often experience
severe eating disorders and other problems because of rapid disease progression and …

Background: Immune checkpoint blockers (ICBs) improve the survival of patients with
cancer, but primary or acquired drug resistance is inevitable. Intestinal microorganisms play …

Εισαγωγή. Οι ασθενείς με μεταστατικό, μη μικροκυτταρικό καρκίνο πνεύμονα (ΜΜΚΠ)
βιώνουν συχνά διαταραχές θρέψης και άλλα προβλήματα ως συνέπεια της ταχείας εξέλιξης …